Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowA New Jersey-based company that acquired Cook Group’s drug-delivery technology unit in late 2017 has plans for a major expansion in Indiana.
Publicly traded Catalent Inc, which bought Cook Pharmica LLC for $950 million, announced Monday that it plans to spend more than $100 million to expand its biologics manufacturing operations in Bloomington, where it will add up to 200 employees by the end of 2024.
The company said it would spend $14 million to expand its biologics packaging capabilities and capacity by renovating 15,000 square feet of space at its plant, adding five packaging suites and a new quality-control laboratory. Construction on the addition is expected to be finished in April.
Catalent said it also plans to expand fill and finish capacity in Bloomington by 79,000 square feet by installing an automated vial-inspection machine and high-speed lines for vials and flexible syringes and cartridges.
The company, which already has 900 employees in Bloomington, expects the new positions to support increased packaging and manufacturing operations.
Catalent’s current 875,000-square-foot plant in Bloomington won the 2017 Facility of the Year Award from the International Society of Pharmaceutical Engineers. The company spent $70 million to redevelop a former RCA television assembly plant into the biopharmaceutical contract manufacturing plant.
The Indiana Economic Development Corp. offered Catalent up to $2.4 million in conditional tax credits based on the job- creation plans. The credits hinge on the company’s ability to meet hiring goals.
The city of Bloomington is considering additional incentives.
Company-wide, Catalent employs more than 11,000 people, including 1,800 scientists, at more than 30 facilities across five continents. Its annual revenue in 2018 was $2.5 billion.
Please enable JavaScript to view this content.